Human Milk Oligosaccharides as Potential Antibiofilm Agents: A Review
Issued Date
2022-12-01
Resource Type
eISSN
20726643
Scopus ID
2-s2.0-85143585555
Journal Title
Nutrients
Volume
14
Issue
23
Rights Holder(s)
SCOPUS
Bibliographic Citation
Nutrients Vol.14 No.23 (2022)
Suggested Citation
Bhowmik A., Chunhavacharatorn P., Bhargav S., Malhotra A., Sendrayakannan A., Kharkar P.S., Nirmal N.P., Chauhan A. Human Milk Oligosaccharides as Potential Antibiofilm Agents: A Review. Nutrients Vol.14 No.23 (2022). doi:10.3390/nu14235112 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/83070
Title
Human Milk Oligosaccharides as Potential Antibiofilm Agents: A Review
Author's Affiliation
Other Contributor(s)
Abstract
Surface-associated bacterial communities called biofilms are ubiquitous in nature. Biofilms are detrimental in medical settings due to their high tolerance to antibiotics and may alter the final pathophysiological outcome of many healthcare-related infections. Several innovative prophylactic and therapeutic strategies targeting specific mechanisms and/or pathways have been discovered and exploited in the clinic. One such emerging and original approach to dealing with biofilms is the use of human milk oligosaccharides (HMOs), which are the third most abundant solid component in human milk after lactose and lipids. HMOs are safe to consume (GRAS status) and act as prebiotics by inducing the growth and colonization of gut microbiota, in addition to strengthening the intestinal epithelial barrier, thereby protecting from pathogens. Moreover, HMOs can disrupt biofilm formation and inhibit the growth of specific microbes. In the present review, we summarize the potential of HMOs as antibacterial and antibiofilm agents and, hence, propose further investigations on using HMOs for new-age therapeutic interventions.